Why the study?
Do angiotensin antagonists with inverse agonistic properties provide better inhibition of post-angioplastic restenosis compared to ACE inhibitors?
Do angiotensin antagonists with inverse agonistic properties provide better inhibition of post-angioplastic restenosis compared to ACE inhibitors?
Angiotensin antagonists with inverse agonistic properties may offer therapeutic benefits in preventing post-angioplastic restenosis where ACE inhibitors are only partially effective.
No takes yet. Share an insight, caveat, or question.
Peptide antagonists merit human restenosis trials; leaves open whether inverse agonism outperforms ACE inhibitors clinically.
Pham et al. (1996) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: